Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial
Authors' conclusion
Among patients undergoing elective CABG with saphenous vein grafting, ticagrelor + aspirin significantly increased graft patency after 1 year vs aspirin alone; there was no significant difference between ticagrelor alone and aspirin alone.
Study context
- Population
- Patients aged 18 to 80 years undergoing elective coronary artery bypass grafting (CABG)461 (92.2%) completed
- Participants
- 500 patients
- Comparison
- Ticagrelor + aspirin or ticagrelor alone vs aspirin alone after CABG
- Ticagrelor + aspirinn = 168
- Ticagrelor alonen = 166
- Aspirin alonen = 166reference
- Primary endpoint
- Saphenous vein graft patency (FitzGibbon grade A), adjudicated by a blinded committee
- Follow-up
- 1 year after CABG
Methodological detailsmulticentre, open-label, 6 tertiary hospitals in China, Enrolment July 2014 to November 2015; follow-up completed January 2017
- Multicentre
- Open-label
- 6 tertiary hospitals in China
- Enrolment July 2014 to November 2015; follow-up completed January 2017
Primary result
As reported in the abstract
Each group vs aspirin aloneDifference (95% CI)P value
Ticagrelor + aspirin
12.2%(5.2%–19.2%)
P < 0.001Ticagrelor alone
6.3%(−1.1% to 13.7%)
P = 0.10Safety
Events
| Outcome | Ticagrelor + aspirin | Ticagrelor alone |
|---|---|---|
| Major bleeding · 1 year | 3 | 2 |
- Major bleeding — Total major bleeding episodes
- 5
Original publication
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA. Published 24 April 2018. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →